News

Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information

Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy oligonucleotides Development of lead product AsiDNA™ in line with plans Paris (France), October 26, 2017 – 08:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – ISIN FR0010095596), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology,…read more →

Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm

Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced the Commercial Court of Paris’ decision in the litigation which started in 2009 between Onxeo on…read more →

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its robust development programs for AsiDNA™ and belinostat, supported by recent promising combination data and preliminary clinical data expected in 2018 Company is well-financed into early 2020, with the resources to support the current clinical development plan Paris (France), October 2, 2017 – 07:00…read more →

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat

Results demonstrate a very strong synergistic effect between AsiDNA™,  first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) This synergy is particularly high for the combination of  its two proprietary assets, AsiDNA™ and belinostat, Potential application of AsiDNA™ in combination with any HDACi fully covered by a key worldwide patent application   Paris (France), September 28, 2017 –…read more →

Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

Paris (France), September 18, 2017 – 8:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, will host a conference call today for its shareholders at 3.00 pm CEST to comment on the main…read more →

Onxeo Grants Exclusive Worldwide License of Validive® developed for the treatment of oral severe mucositis to Monopar Therapeutics

Agreement includes substantial milestone payments up to $108m as well as escalating royalties on future sales Monopar Therapeutics will drive and fund all remaining development, regulatory and commercialization activities Paris (France), September 13, 2017 – 8:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative…read more →

Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma

Paris (France), September 11, 2017 – 8:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced top line results from the phase III ReLive trial of Livatag® (doxorubicine Transdrug™) in adult patients with…read more →

Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the sale of two historical products…read more →

Onxeo Reports First-Half 2017 Results and Business Update

Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core assets on track with multiple short-term milestones Livatag® Phase III results expected before the end of September 2017 Preclinical results of Beleodaq® in other indications / combinations expected by the end of September 2017 AsiDNA™ (systemic administration) Phase I trial…read more →

Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration

Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Paris (France), July 05 2017 – 07h30 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced…read more →

Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Paris (France), May 23, 2017 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 10th unanimous recommendation from the Data Safety Monitoring Board (DSMB), to continue without modification…read more →

Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma

USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims until 2032 Paris (France), May 10, 2017 – 6.30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology,…read more →

Annual General Meeting of April 26, 2017

All ordinary resolutions approved Two new independent directors appointed Renewal of the terms of office of Mrs Judith Greciet, CEO, and Financière de la Montagne Notice for new Extraordinary General Meeting on May 24, 2017 Paris, April 26, 2017 – 8.45 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs…read more →

Onxeo: Q1 2017 financial information and business update

    Revenues up 55% to €1.2 million     Cash position of €21.7 million at March 31, 2017     All strategic assets are progressing according to development plans   Paris, April 26, 2017 – 6.30 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in…read more →

Publication of 2016 Registration Document

Paris (France), April 25, 2017 – 5.45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company’s 2016 Registration Document. The 2016 Registration Document, filed with the French Market Authorities (Autorité des Marchés…read more →